Pharmacokinetics of diuretics and methylxanthines in the neonate

[1]  T. Turmen,et al.  Protein Binding and Bilirubin Displacing Properties of Bumetanide and Furosemide , 1982, Journal of clinical pharmacology.

[2]  T. Turmen,et al.  Relationship of dose and plasma concentrations of caffeine and ventilation in neonatal apnea. , 1981, Seminars in perinatology.

[3]  H. Lagercrantz,et al.  Plasma concentration-effect relationship of theophylline in treatment of apnea in preterm infants , 1980, European Journal of Clinical Pharmacology.

[4]  M. Bonati,et al.  THEOPHYLLINF (T) METABOLISM IN THE PREMATURE NEONATE: 65 , 1980, Pediatric Research.

[5]  J V Aranda,et al.  Metabolism of theophylline to caffeine in human fetal liver. , 1979, Science.

[6]  J. Aranda,et al.  Maturation of caffeine elimination in infancy. , 1979, Archives of disease in childhood.

[7]  R. Royer,et al.  Caffeine, a metabolite of theophylline during the treatment of apnea in the premature infant. , 1979, The Journal of pediatrics.

[8]  H. Bada,et al.  Interconversion of theophylline and caffeine in newborn infants. , 1979, The Journal of pediatrics.

[9]  M. Bethenod,et al.  Metabolism of theophylline to caffeine in premature newborn infants. , 1979, The Journal of pediatrics.

[10]  A. Neims,et al.  Caffeine metabolism in the newborn , 1979, Clinical pharmacology and therapeutics.

[11]  P. Loughnan,et al.  Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. , 1979, The Journal of pediatrics.

[12]  T Turmen,et al.  Methylxanthines in apnea of prematurity. , 1979, Clinics in perinatology.

[13]  D. Sitar,et al.  Pharmacokinetic disposition and protein binding of furosemide in newborn infants. , 1978, The Journal of pediatrics.

[14]  R. Ogilvie.  Clinical Pharmacokinetics of Theophylline , 1978, Clinical pharmacokinetics.

[15]  M. Bonati,et al.  Kinetics and efficacy of theophylline in the treatment of apnea in the premature newborn , 1978, European Journal of Clinical Pharmacology.

[16]  J. Sassard,et al.  [Development of plasma xanthine levels in the treatment of apnea in premature infants]. , 1978, Therapie.

[17]  B. Rumack,et al.  263 FUROSEMIDE PHARMACOKINETICS IN THE PREMATURE NEWBORN , 1978, Pediatric Research.

[18]  H. E. Hansen,et al.  Pharmacokinetics of furosemide in anephric patients and in normal subjects , 1978, European Journal of Clinical Pharmacology.

[19]  J. Aranda,et al.  Effects of furosemide in the newborn , 1978, Clinical pharmacology and therapeutics.

[20]  M. Challamel,et al.  [Pharmacokinetics of theophylline in low birth weight newborn infants]. , 1977, Pediatrie.

[21]  E. Mikkelsen,et al.  Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure , 1977, European Journal of Clinical Pharmacology.

[22]  B. Beermann,et al.  Elimination of furosemide in healthy subjects and in those with renal failure , 1977, Clinical pharmacology and therapeutics.

[23]  K. Midha,et al.  High performance liquid chromatographic and mass spectrometric identification of dimethylxanthine metabolites of caffeine in human plasma. , 1977, Biomedical mass spectrometry.

[24]  A. L. Neese,et al.  Development of a radioimmunoassay for theophylline; Application to studies in premature infants , 1977, Clinical pharmacology and therapeutics.

[25]  R. Branch,et al.  Determinants of response to frusemide in normal subjects. , 1977, British journal of clinical pharmacology.

[26]  S. Shankaran,et al.  The displacement of bilirubin from albumin by furosemide. , 1977, The Journal of pediatrics.

[27]  R. Wennberg,et al.  Displacement of bilirubin from human albumin by three diuretics. , 1977, The Journal of pediatrics.

[28]  T. Gunn,et al.  Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. , 1977, The Journal of pediatrics.

[29]  W. Jusko,et al.  Theophylline pharmacokinetics in premature infants with apnea. , 1976, The Journal of pediatrics.

[30]  A H Neims,et al.  Pharmacokinetic aspects of theophylline in premature newborns. , 1976, The New England journal of medicine.

[31]  A. Neims,et al.  Drug utilization in a newborn intensive care unit. , 1976, The Journal of pediatrics.

[32]  H. Nagasawa,et al.  Relationship of urinary metabolites of theophylline to serum theophylline levels , 1976, Clinical pharmacology and therapeutics.

[33]  S. Sved,et al.  The human metabolism of caffeine to theophylline. , 1976, Research communications in chemical pathology and pharmacology.

[34]  A. Rosén,et al.  On the fate of furosemide in man , 1975, European Journal of Clinical Pharmacology.

[35]  R. Matthay,et al.  Theophylline-induced seizures in adults. Correlation with serum concentrations. , 1975, Annals of internal medicine.

[36]  M. Horning,et al.  Drug metabolism in the human neonate. , 1975, Life sciences.

[37]  B. Lindström,et al.  Gas chromatographic determination of furosemide in plasma using an extractive alkylation technique and an electron capture detector. , 1974, Journal of chromatography.

[38]  N. Levin,et al.  Pharmacokinetics of furosemide in advanced renal failure , 1974, Clinical pharmacology and therapeutics.

[39]  A. Forrey,et al.  Pharmacokinetics of furosemide in normal subjects and functionally anephric patients , 1974, Clinical pharmacology and therapeutics.

[40]  A. Pruitt,et al.  EFFECT OF ALBUMIN AND DRUG CONCENTRATION ON THE BINDING OF FUROSEMIDE , 1974, Pediatric Research.

[41]  D. Davies,et al.  Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide , 1974, Clinical pharmacology and therapeutics.

[42]  C. Edelmann,et al.  The maturing kidney , 1969 .

[43]  B. Calesnick,et al.  Absorption and Excretion of Furosemide-S35 in Human Subjects , 1966, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[44]  H. E. Williamson,et al.  Influence of probenecid and alterations in acid-base balance of the saluretic activity of furosemide. , 1965, The Journal of pharmacology and experimental therapeutics.

[45]  H. Cornish,et al.  A study of the metabolism of theobromine, theophylline, and caffeine in man. , 1957, The Journal of biological chemistry.

[46]  W. Jusko,et al.  Factors affecting theophylline pharmacokinetics in premature infants with apnea. , 1980, Developmental pharmacology and therapeutics.

[47]  K. Simons,et al.  Theophylline toxicity in term infants. , 1980, American journal of diseases of children.

[48]  T. Gunn,et al.  Sequelae of caffeine treatment in preterm infants with apnea. , 1979, The Journal of pediatrics.

[49]  F. Simons,et al.  Physiologic changes induced by theophylline in the treatment of apnea in preterm infants. , 1978, The Journal of pediatrics.

[50]  W. Oh,et al.  The pharmacologic effects of furosemide therapy in the low-birth-weight infant. , 1978, The Journal of pediatrics.

[51]  James M. Adams,et al.  Serum Digoxin Levels in Premature-Infants , 1976 .

[52]  J. Loggie,et al.  Renal function and diuretic therapy in infants and children. Part I. , 1975, The Journal of pediatrics.

[53]  E. Eilertsen,et al.  Pharmacological properties of 3-n-butylamino-4-phenoxy-5-sulfamylbenzoic acid (Bumetanide), a new potent diuretic. , 1972, Arzneimittel-Forschung.